Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.58 |
| ▸ | NR1H3 | Q13133 | 2/20 | 0.55 |
| ▸ | SCN2A | Q99250 | 3/20 | 0.53 |
| ▸ | CA9 | Q16790 | 3/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | AR | P10275 | 1/20 | 0.52 |
| ▸ | ELANE | P08246 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5573414 | 0.85 | POLB (0.58) | PGRNR1H3CA9CA12CA1 | |
| SCHEMBL4649471 | 0.83 | KMT2A (0.78) | KMT2AMEN1NR1H3SCN2ACA9 | |
| SCHEMBL5819062 | 0.82 | KMT2A (0.60) | KMT2AMEN1NR1H3SCN2ACA9 | |
| SCHEMBL11520720 | 0.82 | ESR1 (0.58) | PGRKMT2AMEN1NR1H3SCN2A | |
| SCHEMBL22580619 | 0.82 | ESR1 (0.49) | PGRCA9CA12CA1AR | |
| SCHEMBL16863011 | 0.82 | HSPA1A (0.67) | PGRKMT2ANR1H3ELANEPOLB | |
| SCHEMBL21067769 | 0.81 | ADORA2A (0.56) | PGR | |
| SCHEMBL29870828 | 0.80 | GRM5 (0.54) | KMT2AMEN1NR1H3SCN2A | |
| SCHEMBL16113584 | 0.80 | GRM5 (0.54) | KMT2AMEN1NR1H3SCN2A | |
| SCHEMBL31036614 | 0.80 | POLB (0.49) | PGRKMT2AMEN1NR1H3CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112204076-B | Resin composition, prepreg, metal foil-clad laminate, resin sheet, and printed wiring board | 三菱瓦斯化学株式会社 | 2023-10-24 | — | — | CN | disclosed |
| WO-2020124500-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | 江苏凯迪恩医药科技有限公司 | 2020-06-25 | — | — | WO | disclosed |
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2019-07-16 | — | — | US | disclosed |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2019-01-01 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE | 2017-04-27 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-9464065-B2 | Compounds and methods for inducing chondrogenesis | THE SCRIPPS RESEARCH INSTITUTE (US) | 2016-10-11 | — | — | US | disclosed |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | THE ASSAY DEPOT, INC. | 2016-07-28 | — | — | US | disclosed |
| WO-2012129562-A2 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-09-27 | — | — | WO | disclosed |
| US-4159262-A | POLYIMIDES, POLYBENZIMIDAZOLES, POLYQUINOXALINES, POLYIMIDAZOPYRROLONES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR, NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1979-06-26 | — | — | US | disclosed |
| US-4061856-A | TO 1,3,5-TRIAZINES, SULFONIC, SULFINIC, PHOSPHONIC OR PHOSPHINIC ACID OR METAL ACETYLACETONATE CATALYST | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE ADMINISTRATOR OF THE NATIONAL AERONAUTICS AND SPACE ADMINISTRATION (US) | 1977-12-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10351568-B2 | Compositions and methods for enhancing proteasome activity | PSMG3, PSME3, PSMB11 | PGR 4424/4885KMT2A 2159/4885MEN1 2411/4885 |
| US-10166237-B2 | Compounds and methods for inducing chondrogenesis | COL2A1, BMP4, BMP2 | PGR 3395/4885KMT2A 3000/4885MEN1 4660/4885 |
| US-20170112843-A1 | COMPOUNDS AND METHODS FOR INDUCING CHONDROGENESIS | COL2A1, BMP4, BMP2 | PGR 3395/4885KMT2A 3000/4885MEN1 4660/4885 |
| US-20160214989-A1 | Compositions and Methods for Enhancing Proteasome Activity | PSMG3, PSME3, PSMB11 | PGR 4424/4885KMT2A 2159/4885MEN1 2411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.